Company profile
KAILERA THERAPEUTICS, INC.
NASDAQ:KLRABiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| RIBUPATIDE | phase3 | — | 5 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07044401 | phase1 | completed | 2025-07-14 | 2025-11-13 | Kailera | A Single-dose Study to Investigate the Effect of Injection Site on KAI-9531 Relative Bioavailability in a Range of Body Mass Indices |
| NCT07793929 | phase1 | recruiting | 2026-09-08 | 2028-02-08 | Kailera | A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of Ribupatide |
| NCT07294898 | phase1 | completed | 2025-12-15 | 2026-01-26 | Kailera | A Study to Investigate the Effect of a Low-fat Meal and Evening Dosing on KAI-7535 in Participants Living With Obesity or Overweight |
| NCT07497880 | phase2 | active_not_recruiting | 2026-04-06 | 2027-07-07 | Kailera | Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity |
| NCT07458269 | phase2 | active_not_recruiting | 2026-03-04 | 2027-05-01 | Kailera | Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes |
FDA applications (0)
No records yet.